BT3:FRA
Lineage Cell Therapeutics Inc
€ 0.82
arrow_upward
+1.23%(+0.0100) 1D
10-р сарын 8, 08:01:28 (GMT+2) · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BT3...
Open
€ 0.82
High
€ 0.82
Low
€ 0.82
Mkt. cap
239.12 сая
Avg. vol.
37.00
Volume
0.00
52-wk high
€ 1.69
52-wk low
€ 0.78
No. of employees
75
Open
€ 0.82
High
€ 0.82
Low
€ 0.82
Mkt. cap
239.12 сая
Avg. vol.
37.00
Volume
0.00
52-wk high
€ 1.69
52-wk low
€ 0.78
No. of employees
75
News stories
From web sources and news partners
GlobeNewswire
·
38 минутын өмнө
ONAR Advances Nasdaq Listing Preparation Following Advertise Purple Acquisition and Financing
Simply Wall Street
·
43 минутын өмнө
Applied Materials (AMAT) Deepens AI Chipmaking R And D With Major Foundry Partner
Yahoo Finance
·
38 минутын өмнө
UMeWorld Upgrades to OTCQB Venture Market; Engages ARC Group Securities for Proposed Nasdaq Uplisting
Bloomberg.com
·
2 цагийн өмнө
AI Bubble Risks Worst S&P 500 Crash Since 2008, Strategist Says
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc